KNO yields 1.09% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, KNO + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNO + JNJ for your $10,000?
KNO is actively managed to invest in a portfolio of large- and midcap companies perceived to be innovative potentially capturing outperformance through a knowledge effect. The fund will invest in developed market countries excluding Hong Kong, non-US stocks will have at least 40% exposure to these markets. KNOs proprietary model adjusts historical financial statements for intangibles and capitalizes a companys financial strength, profitability, and investment in innovation. After these adjustments, the fund adviser selects the most liquid companies. Intangible assets include R&D, advertising, brand development, and employee training expenses. Prior to May 26, 2020, the fund tracked the Knowledge Leaders Developed World Index. Also, Knowledge Leaders Capital, LLC replaced Exchange Traded Concepts, LLC as its investment adviser. On July 22, 2023, the ETF acquired all assets and liabilities of the Knowledge Leaders Developed World ETF (KLDW), which had about $130 million in assets.
Full KNO Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.